







GAP

According to data published in 2021*

47%

of the global population has little to no access to diagnostics

81%

of the LMIC population lacks access to the most basic tests

Limitations of centralized testing approaches:

- Limited access
- Logistical challenges
- High costs

- Long turn-around times
- Dependency on specialized infrastructure
- Need for highly skilled workforce

MOLBIO - CHANGING PARADIGMS

Designed to meet the unique needs of diverse clinical settings, Molbio's innovative point-of-care technologies enable universal access to quality diagnostics. Our solutions are:



Compact & portable



Rapid & accurate



Cost effective



Adaptable & future-ready

^{*}Source: Lancet Commission



OUR RANGE OF PRODUCTS

Truenat®

Molbio's flagship product — a point-of-care real time PCR platform for diagnosis of multiple infectious diseases.







PRORAD ATLAS

An ultra-portable digital X-ray system for last-mile imaging needs.





Thermalytix[®]

A novel AI based, non-intrusive, radiation-free, breast cancer screening solution.





YOUR SETTINGS, OUR SOLUTIONS

Robust and highly adaptable, our products are designed for easy deployment in varied settings.


















GLOBAL PRESENCE & IMPACT

Founded in 2000, Molbio Diagnostics has established a strong global presence, serving communities in 85+ countries worldwide and touching more than 40 million lives.











VOICES FROM THE FIELD

Breaking barriers to reach the last mile!



"The roll-out of Truenat under the iNTP in Bantayan Island Philippines has significantly boosted the detection of presumptive TB instances."

Dr. Samantha Tinsay, Municipal Health Officer, Bantayan, Cebu, Phillipines.

Rapid & accurate test!



"Truenat has effectively addressed the logistical challenges making same-day 'test and treat' a reality in Uganda."

Mr. Magada David, Lab Technologist, Buwasa HCIV.

Advancing hepatitis elimination.



"Truenat has made community-led hepatitis care with same-day 'test and treat' for HCV feasible and effective, moving us closer to the WHO 2030 elimination target."

Nalinikanta Rajkumar, Community Network of Empowerment, Manipur, India.

Faster turnaround time and reducing transmission risk.



"Truenat at peripheral Nigeria has cut down the turnaround time for TB diagnosis to 24 hours for the majority of cases, enabling faster treatment initiation and reduced transmission."

Independent study published on PHA



VOICES OF TRUST



"Truenat, a platform developed for multiple pathogens, if put in a primary health centre can be used not only for TB but also for influenza, dengue, malaria, hepatitis, etc."

Dr. Soumya Swaminathan, Former Chief Scientist, WHO, Geneva.



"Truenat's simplicity, portability, battery and solar power make it a perfect device for deployment at lower levels in Zimbabwe, especially when accessibility is challenging. It enables us to do better in TB diagnosis."

Tanaka Sakubana, National TB Laboratories Coordinator, MoH, Zimbabwe.

YOUR INPUTS DRIVE OUR R&D

FEEDBACK >

"Prolonged power outages and lack of charging station to recharge the machine slows down our interventions."

Dr. F Kavenga, MOHCC, Zimbabwe.

SOLUTION >

Molbio introduces Truelux, a portable solar-powered station that tackles challenges around power outage to recharge the Truenat machines.



OUR COMMITMENT TO KEEP YOU FUTURE READY

Our R&D philosophy for clinical diagnostics is built on four pillars of care:

INDEPENDENT

CONTINUOUS

COST-EFFECTIVE


CONNECTED

Our team of scientists and engineers continue to innovate and develop new solutions to address evolving needs in global healthcare across multiple clinical applications.

- Molecular diagnostics
- Radiology
- Histopathology

- Hemoglobinopathy
- Microbiology
- Biochemistry











Molbio Diagnostics Limited

L-46, Phase II D, Verna Industrial Estate, Verna, Goa, 403 722, India.

Tel: +91 832 2783267

Web site: www.molbiodiagnostics.comEmail: sales@molbiodiagnostics.com